Tibra Equities Europe’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Tibra Equities Europe’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-91,200	Closed	-$339K	–	243
2021 Q2	$339K	Buy	+91,200	New	+$304K	0.1%	90
2019 Q2	–	Sell	-22,778	Closed	-$217K	–	481
2019 Q1	$217K	Buy	+22,778	New	+$90.2K	0.02%	366

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Tibra Equities Europe's PHAS Position: Q3 2021 in Review

Tibra Equities Europe sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2021, closing a stake of 91,200 shares — an estimated $339K sold.

Tibra Equities Europe first reported a position in PHAS in Q1 2019 and held it in 2 quarters. The position peaked at $339K in Q2 2021. 61 funds tracked by Wall St. Rank hold PHAS as of Q3 2021.

Tibra Equities Europe reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Tibra Equities Europe sold 91,200 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $339K.
Tibra Equities Europe first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
Tibra Equities Europe's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $339K in Q2 2021.
61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.